GlassScriptPhysician profile
Malkiah Levine
NPI 1336649755
$1,914.20
in general payments reported to CMS, 2019-2025
18 companies · $330 in 2025
The $330 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $217 · 2022: $439 · 2023: $618 · 2024: $310 · 2025: $330.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,257.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,257.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $366.47 | 2021-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $264.53 | 2021-2024 | |
| Abbvie INC. | $230.86 | 2022-2025 | |
| Genzyme Corporation | $218.32 | 2024-2025 | |
| Pfizer INC. | $146.02 | 2021-2025 | |
| Alexion Pharmaceuticals, INC. | $104.21 | 2022-2025 | Ultomiris |
| Genentech USA, INC. | $100.80 | 2022 | |
| Paratek Pharmaceuticals, INC. | $83.88 | 2023 | Nuzyra |
| Gilead Sciences, INC. | $82.51 | 2021-2025 | Veklury |
| Merck Sharp & Dohme LLC | $67.02 | 2023-2025 | Zerbaxa, Dificid, Recarbrio |
| Mallinckrodt Hospital Products INC. | $53.33 | 2024 | Terlivaz |
| Xeris Pharmaceuticals, INC. | $48.76 | 2023 | Gvoke Hypopen |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $45.51 | 2024-2025 | Xifaxan |
| E.R. Squibb & Sons, L.L.C. | $32.92 | 2021-2025 | Eliquis |
| Astrazeneca Pharmaceuticals LP | $21.10 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $19.78 | 2024 | Lifevest |
| Evoke Pharma, INC. | $15.04 | 2024 | |
| Novo Nordisk INC | $13.14 | 2024 | Wegovy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Malkiah Levine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.